[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Longhua Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100629719","phase-2-chaigui-longmu-ejiao-paste-for-ischemic-heart-disease-100629719",false,"NCT07478328","Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","A Randomized, Double-Blind Clinical Trial of Chaigui Longmu Ejiao Paste in the Treatment of Ischemic Heart Disease With Internal and External Controls","Inclusion Criteria:\n\n1. Age 18-75 years, both sexes eligible;\n2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks;\n3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying\u002Fstabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages;\n4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of \"thoracic yang deficiency with heart vessel stasis\" (or \"chest yang insufficiency with heart meridian blood stasis\"), with primary symptoms: chest oppression\u002Fpain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings;\n5. Has signed the informed consent form and is willing to participate voluntarily in the study.\n\nExclusion Criteria:\n\n1. Acute coronary syndrome or patients requiring emergency revascularization;\n2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks;\n3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment);\n4. Severe heart failure (NYHA functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate;\n5. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × upper limit of normal, or creatinine \\> 1.5 × upper limit of normal);\n6. Known allergy to any component of the study formula;\n7. Women who are pregnant, lactating, or planning pregnancy;\n8. Patients who have participated in other clinical trials within the past 3 months;\n9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.",[27],"Ischemic Heart Disease","NOT_YET_RECRUITING","2026-03-13",{"date":31,"type":32},"2026-03-17","ACTUAL",{"date":34,"type":21},"2026-03-08",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Longhua Hospital","OTHER",""]